No Data
Chongqing Zhifei Biological Products (300122.SZ): Application for clinical trial of adjuvanted trivalent influenza vaccine has been accepted.
Chongqing Zhifei Biological Products (300122.SZ) announced that its wholly-owned subsidiary Anhui Zhifei Longkema Biological Pharmaceutical Co., Ltd. (...)
Chongqing Zhifei Biological Products Co., Ltd. (SZSE:300122) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Chongqing Zhifei Biological Products (300122.SZ): Mid-term profit distribution of 10 shares for every 2 yuan in 2024. The equity registration date is December 24.
On December 17, Gelonghui announced that Chongqing Zhifei Biological Products (300122.SZ) has released its mid-term equity distribution plan for 2024: based on the company's total share capital of 2,393,789,747 shares, a cash distribution of 2.000000 yuan per 10 shares (tax included) will be made to all Shareholders. The record date for this equity distribution is December 24, 2024, and the ex-rights and ex-dividend date is December 25, 2024.
Chongqing Zhifei Biological Products (300122.SZ) intends to distribute 2 yuan for every 10 shares, with the ex-rights and ex-dividend date on December 25.
Chongqing Zhifei Biological Products (300122.SZ) announced that the proposed distribution of equity for the mid-term in 2024 is: to distribute to all Shareholders every 10...
Chongqing Zhifei Biological Products (SZSE:300122) Earnings and Shareholder Returns Have Been Trending Downwards for the Last Three Years, but the Stock Advances 4.4% This Past Week
Chongqing Zhifei Biological, GSK Adjust Terms of Cooperation Agreement
102884128 : getting disappointed with this counter. every day drop.